688192 迪哲医药-U
已收盘 09-01 15:00:01
资讯
新帖
简况
迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效
智通财经 · 09-01 08:44
迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效
迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%
证券之星 · 08-31 17:44
迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%
迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资
智通财经 · 08-28
迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资
每周股票复盘：迪哲医药（688192）股东户数增18.73%
证券之星 · 08-23
每周股票复盘：迪哲医药（688192）股东户数增18.73%
迪哲医药（688192）披露舒沃哲两项非小细胞肺癌临床研究数据获选2026年世界肺癌大会展示，8月21日股价下跌5.07%
证券之星 · 08-21
迪哲医药（688192）披露舒沃哲两项非小细胞肺癌临床研究数据获选2026年世界肺癌大会展示，8月21日股价下跌5.07%
每周股票复盘：迪哲医药（688192）拟调整董事会人数至7人
证券之星 · 08-16
每周股票复盘：迪哲医药（688192）拟调整董事会人数至7人
迪哲医药（688192）披露召开2026年第三次临时股东会的通知，8月4日股价上涨1.68%
证券之星 · 08-04
迪哲医药（688192）披露召开2026年第三次临时股东会的通知，8月4日股价上涨1.68%
每周股票复盘：迪哲医药（688192）与阿斯利康签署授权许可协议
证券之星 · 08-02
每周股票复盘：迪哲医药（688192）与阿斯利康签署授权许可协议
迪哲医药（688192）披露与阿斯利康签署授权许可协议暨关联交易议案获通过，7月30日股价下跌4.07%
证券之星 · 07-30
迪哲医药（688192）披露与阿斯利康签署授权许可协议暨关联交易议案获通过，7月30日股价下跌4.07%
每周股票复盘：迪哲医药（688192）获6亿美元首付款
证券之星 · 07-26
每周股票复盘：迪哲医药（688192）获6亿美元首付款
迪哲医药(688192.SH)发预亏，预计半年度归母净亏损2.1亿元左右
智通财经 · 07-23
迪哲医药(688192.SH)发预亏，预计半年度归母净亏损2.1亿元左右
新股消息 | 迪哲医药(688192.SH)港股IPO招股书失效
智通财经 · 07-23
新股消息 | 迪哲医药(688192.SH)港股IPO招股书失效
迪哲医药（688192）披露拟与阿斯利康签署舒沃哲®全球许可协议，7月22日股价下跌1.49%
证券之星 · 07-22
迪哲医药（688192）披露拟与阿斯利康签署舒沃哲®全球许可协议，7月22日股价下跌1.49%
每周股票复盘：迪哲医药（688192）与阿斯利康签6亿美元协议
证券之星 · 07-19
每周股票复盘：迪哲医药（688192）与阿斯利康签6亿美元协议
迪哲医药（688192）披露关于与阿斯利康签署授权许可协议暨关联交易的议案，7月15日股价上涨20.01%
证券之星 · 07-15
迪哲医药（688192）披露关于与阿斯利康签署授权许可协议暨关联交易的议案，7月15日股价上涨20.01%
7月15日龙虎榜机构席位买卖详情
南方财经网 · 07-15
7月15日龙虎榜机构席位买卖详情
半年BD狂飙千亿、龙头预增13倍！创新药涨停潮再起
格隆汇 · 07-15
半年BD狂飙千亿、龙头预增13倍！创新药涨停潮再起
迪哲医药-U将获6亿美元预付款及最高9亿美元里程碑付款
美股速递 · 07-14
迪哲医药-U将获6亿美元预付款及最高9亿美元里程碑付款
异动快报：迪哲医药-U（688192）7月14日13点0分触及涨停板
证券之星 · 07-14
异动快报：迪哲医药-U（688192）7月14日13点0分触及涨停板
每周股票复盘：迪哲医药（688192）因股价涨幅偏离值累计达30%登龙虎榜
证券之星 · 07-05
每周股票复盘：迪哲医药（688192）因股价涨幅偏离值累计达30%登龙虎榜
暂无数据
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药-U","latestPrice":57.85,"timestamp":1788246001000,"preClose":58.28,"halted":0,"volume":4031031,"delay":0,"changeRate":-0.0074,"floatShares":461000000,"shares":465000000,"eps":-1.2836,"marketStatus":"已收盘","change":-0.43,"latestTime":"09-01 15:00:01","open":59.48,"high":59.88,"low":57.04,"amount":234000000,"amplitude":0.0487,"askPrice":57.86,"askSize":51,"bidPrice":57.85,"bidSize":9,"shortable":0,"etf":0,"ttmEps":-1.2836,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":5,"adr":0,"adjPreClose":58.28,"symbolType":"stock_kcb","openAndCloseTimeList":[[1788226200000,1788233400000],[1788238800000,1788246000000]],"highLimit":64.11,"lowLimit":52.45,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":465165842,"isCdr":false,"pbRate":23.81,"roa":"--","roe":"--","epsLYR":-1.71,"committee":-0.457364,"marketValue":26910000000,"turnoverRate":0.0087,"status":1,"afterMarket":{"amount":63635,"volume":1100,"close":57.85,"buyVolume":597,"sellVolume":0,"time":1788248037746,"indexStatus":"已收盘 09-01 15:30:00","preClose":58.28},"floatMarketCap":26681000000},"requestUrl":"/m/hq/s/688192/tweets","defaultTab":"tweets","newsList":[{"id":"2664881161","title":"迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881161","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664881161?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:44","pubTimestamp":1788223497,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2026年7月14日与AstraZeneca UK Limited(以下简称“阿斯利康”)签署《许可协议》，授予阿斯利康在全球范围内独家开发、商业化舒沃哲®的权利。协议约定的协议生效条件已全部满足，协议于2026年8月31日正式生效。阿斯利康将于今年第四季度在美国实现舒沃哲®商业化。公司将获得阿斯利康支付的一次性、不可返还的首付款6亿美元，最高达4 亿美元的临床开发里程碑款项以及最高达5亿美元的销售里程碑款项，此外公司将获得按舒沃哲®全球销售额最高到低双位数的阶梯式比例的特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","688192","BK0239","BK1161","09939","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071350","title":"迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071350","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663071350?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:44","pubTimestamp":1788169497,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，迪哲医药报收于58.28元，较前一交易日下跌0.66%，最新总市值为271.1亿元。该股当日开盘57.87元，最高59.58元，最低57.5元，成交额达3.55亿元，换手率为1.32%。迪哲医药近日披露公告，公司自主研发的舒沃哲新增适应症上市申请已获美国FDA受理，拟用于一线治疗EGFR exon20ins的局部晚期或转移性非小细胞肺癌成人患者。该适应症在中国也已获NMPA受理并纳入优先审评，此前已获中美突破性疗法认定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100024818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK1574","BK1515","159938","BK1161","BK0239","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662034757","title":"迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资","url":"https://stock-news.laohu8.com/highlight/detail?id=2662034757","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662034757?lang=zh_cn&edition=full","pubTime":"2026-08-28 08:25","pubTimestamp":1787876738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2026年8月27日重新向香港联合交易所有限公司(以下简称“香港联交所”)递交了发行H股股票并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请材料。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","BK1574","159938","BK0239","688192","IPOS","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661110862","title":"每周股票复盘：迪哲医药（688192）股东户数增18.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661110862","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661110862?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:53","pubTimestamp":1787424789,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，迪哲医药报收于59.0元，较上周的60.91元下跌3.14%。本周，迪哲医药8月18日盘中最高价报62.65元。公司公告汇总：公司与阿斯利康签署许可协议，授予舒沃哲全球独家开发和商业化权利，获得6亿美元首付款。股本股东变化截至2026年6月30日，公司股东户数为1.29万户，较3月31日增加2041户，增幅18.73%。户均持股数量由上期的4.26万股减少至3.6万股，户均持股市值为143.58万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1161","BK1515","159938","BK0239","BK1574","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661303296","title":"迪哲医药（688192）披露舒沃哲两项非小细胞肺癌临床研究数据获选2026年世界肺癌大会展示，8月21日股价下跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661303296","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661303296?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:15","pubTimestamp":1787321724,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，迪哲医药报收于59.0元，较前一交易日下跌5.07%，最新总市值为274.45亿元。该股当日开盘60.45元，最高61.1元，最低58.1元，成交额达5.38亿元，换手率为1.96%。近日，迪哲医药发布自愿披露公告，其自主研发的舒沃哲两项非小细胞肺癌领域的最新临床研究数据获选在2026年世界肺癌大会上以壁报形式展示。目前相关适应症尚处临床试验阶段，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100045408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","159938","688192","BK1574","BK1161","09939","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659175175","title":"每周股票复盘：迪哲医药（688192）拟调整董事会人数至7人","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175175","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175175?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:50","pubTimestamp":1786816223,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，迪哲医药报收于60.91元，较上周的56.0元上涨8.77%。本周，迪哲医药8月13日盘中最高价报63.66元。迪哲医药当前最新总市值283.33亿元，在化学制药板块市值排名15/149，在两市A股市值排名704/5207。本周关注点公司公告汇总：迪哲医药拟调整董事会人数为7人，并选举第三届董事会成员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1161","688192","BK1515","BK0239","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656855286","title":"迪哲医药（688192）披露召开2026年第三次临时股东会的通知，8月4日股价上涨1.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656855286","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656855286?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:17","pubTimestamp":1785853035,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，迪哲医药报收于50.26元，较前一交易日上涨1.68%，最新总市值为233.79亿元。该股当日开盘50.4元，最高51.9元，最低49.78元，成交额达4.58亿元，换手率为1.96%。近日，迪哲（江苏）医药股份有限公司发布《关于召开2026年第三次临时股东会的通知》。公告显示，公司将于2026年8月20日召开2026年第三次临时股东会，会议采用现场投票与网络投票相结合的方式，股权登记日为2026年8月14日。中小投资者对董事选举议案将单独计票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK1161","BK1574","BK1515","BK0239","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656196943","title":"每周股票复盘：迪哲医药（688192）与阿斯利康签署授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2656196943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656196943?lang=zh_cn&edition=full","pubTime":"2026-08-02 03:17","pubTimestamp":1785611830,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，迪哲医药报收于51.05元，较上周的55.6元下跌8.18%。本周，迪哲医药7月27日盘中最高价报57.3元。本周关注点公司公告汇总：迪哲医药股东大会通过与阿斯利康签署授权许可协议的议案，获99.9536%同意票。议案获普通股股东同意票186,456,608股，占比99.9536%，中小投资者同意比例为99.4234%。北京市中伦律师事务所出具法律意见书，确认会议召集、召开程序及表决结果合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","688192","BK1161","159938","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655805121","title":"迪哲医药（688192）披露与阿斯利康签署授权许可协议暨关联交易议案获通过，7月30日股价下跌4.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655805121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655805121?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:17","pubTimestamp":1785421034,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，迪哲医药报收于51.16元，较前一交易日下跌4.07%，最新总市值为237.98亿元。近日，迪哲（江苏）医药股份有限公司召开2026年第二次临时股东会，审议通过《关于与阿斯利康签署授权许可协议暨关联交易的议案》。会议于2026年7月30日以现场和网络投票方式召开，出席会议股东188人，代表表决权40.1024%。议案获普通股股东同意票186,456,608股，占比99.9536%，中小投资者对该议案同意比例为99.4234%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000039620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","688192","BK1574","BK0239","BK1161","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654105253","title":"每周股票复盘：迪哲医药（688192）获6亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2654105253","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654105253?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:12","pubTimestamp":1784999531,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，迪哲医药报收于55.6元，较上周的61.42元下跌9.48%。本周，迪哲医药7月22日盘中最高价报65.9元。本周关注点来自业绩披露要点：迪哲医药预计2026年上半年营收5.22亿元，同比增长约47.04%。来自公司公告汇总：迪哲医药拟授予阿斯利康舒沃哲全球独家权利，获6亿美元首付款。来自业绩披露要点：归属于母公司净亏损约2.1亿元，同比减少44.35%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688192","BK0239","BK1161","159938","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653746090","title":"迪哲医药(688192.SH)发预亏，预计半年度归母净亏损2.1亿元左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2653746090","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653746090?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:20","pubTimestamp":1784802006,"startTime":"0","endTime":"0","summary":"预计2026年半年度归属于母公司所有者的扣除非经常性损益后的净亏损2.31亿元左右，同比亏损减少44.90%左右。公司2026年半年度营业收入大幅增长，同时产品研发进展较为顺利，研发投入仍保持较高水平，预计2026年半年度将继续出现归属于母公司所有者的净利润为负的情况，但公司主营业务、核心竞争力没有发生重大不利变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","159938","688192","BK1574","09939","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653718648","title":"新股消息 | 迪哲医药(688192.SH)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2653718648","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653718648?lang=zh_cn&edition=full","pubTime":"2026-07-23 10:44","pubTimestamp":1784774673,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迪哲(江苏)医药股份有限公司(简称：迪哲医药(688192.SH))于2026年1月23日所递交的港股招股书满6个月，于2026年7月23日失效，递表时高盛和华泰国际为其联席保荐人。据招股书，迪哲医药是一家处于商业化阶段的生物制药公司，公司的核心治疗领域是肿瘤及血液系统疾病。公司的上市产品舒沃哲®是全球范围内唯一获批用于治疗EGFR 20号外显子插入突变型肺癌的小分子表皮生长因子受体酪氨酸激酶抑制剂。于2023年度、2024年度、2025年截至9月30日止九个月，该公司实现收入分别为9128.9万元、3.6亿元、5.86亿元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","REDS","688192","BK1574","BK4588","BK1515","159938","KCE","IPOS","BK1161","FRHC","VXUS","KCAI","BK4127","BK0239","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653676503","title":"迪哲医药（688192）披露拟与阿斯利康签署舒沃哲®全球许可协议，7月22日股价下跌1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653676503","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653676503?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:14","pubTimestamp":1784729661,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，迪哲医药报收于60.86元，较前一交易日下跌1.49%，最新总市值为283.1亿元。该股当日开盘60.1元，最高65.9元，最低60.1元，成交额达11.57亿元，换手率为3.96%。近日，迪哲医药披露公告，拟与阿斯利康签署《许可协议》，授予其全球范围内独家开发、商业化舒沃哲的权利。阿斯利康为公司关联法人，本次交易构成关联交易，但不构成重大资产重组。该事项已获董事会审议通过，尚需提交股东会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239","BK1161","BK1515","159938","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237196","title":"每周股票复盘：迪哲医药（688192）与阿斯利康签6亿美元协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237196","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652237196?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:31","pubTimestamp":1784395867,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，迪哲医药报收于61.42元，较上周的46.76元上涨31.35%。本周，迪哲医药7月16日盘中最高价报69.58元。来自公司公告汇总：迪哲医药与阿斯利康签署授权许可协议，获6亿美元首付款。公司公告汇总迪哲（江苏）医药股份有限公司与阿斯利康签署《许可协议》，授予其全球范围内独家开发、商业化舒沃哲的权利。迪哲医药发布股票交易异常波动公告，2026年7月13日至15日连续三日收盘价涨幅偏离值累计达30%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09939","159938","BK1515","BK1574","BK1161","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651422456","title":"迪哲医药（688192）披露关于与阿斯利康签署授权许可协议暨关联交易的议案，7月15日股价上涨20.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651422456","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651422456?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:23","pubTimestamp":1784107401,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，迪哲医药报收于67.6元，较前一交易日上涨20.01%，最新总市值为314.45亿元。该股当日开盘62.66元，最高67.6元，最低62.0元，成交额达10.57亿元，换手率为3.42%。迪哲（江苏）医药股份有限公司于近日披露《关于召开2026年第二次临时股东会的通知》。本次会议将审议《关于与阿斯利康签署授权许可协议暨关联交易的议案》，中小投资者将单独计票，关联股东AstraZeneca AB需回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500032881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","09939","159938","BK1574","688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651567894","title":"7月15日龙虎榜机构席位买卖详情","url":"https://stock-news.laohu8.com/highlight/detail?id=2651567894","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651567894?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:18","pubTimestamp":1784107080,"startTime":"0","endTime":"0","summary":"南财智讯7月15日电，盘后数据显示，因当日异动登上龙虎榜的个股中，34只沪深A股龙虎榜出现了机构的身影，机构合计净买入30394.26万元，具体来看，机构净买入19只个股，净卖出15只个股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607153807534381.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807534381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0132","LU1979443071.USD","002821","BK0239","BK0094","BK0139","603459","BK0125","BK0188","BK0196","BK0229","BK0197","300821","BK0217","002185","BK0028","BK0198","LU1328615791.USD","688192","BK0214","LU1934453819.USD","002558","BK0121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651879434","title":"半年BD狂飙千亿、龙头预增13倍！创新药涨停潮再起","url":"https://stock-news.laohu8.com/highlight/detail?id=2651879434","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651879434?lang=zh_cn&edition=full","pubTime":"2026-07-15 13:50","pubTimestamp":1784094601,"startTime":"0","endTime":"0","summary":"政策密集加码","market":"sh","thumbnail":"https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5584162","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["002940","BK0239","BK0077","06978","BK0146","MEDX","688192","BK0070","159992","002317","BD","300149","BK0060","BK0216","BK1574","BK0012","IBBQ","600664","BK0188","BK1161","000566","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168929538","title":"迪哲医药-U将获6亿美元预付款及最高9亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1168929538","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168929538?lang=zh_cn&edition=full","pubTime":"2026-07-14 14:11","pubTimestamp":1784009481,"startTime":"0","endTime":"0","summary":"迪哲医药-U宣布，公司将获得一笔高达6亿美元的预付款，并有望在此基础上获得总计不超过9亿美元的里程碑付款。这一重大财务安排标志着公司核心资产价值获得国际认可，也为后续研发注入了强劲动力。通过灵活而富有前瞻性的支付结构，合作方展现了对其产品管线潜力的坚定信心。此次交易不仅优化了公司的现金流状况，更将助力其加速推进关键临床项目，在全球创新药领域持续深化布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909247.SGD","LU0784383803.USD","LU2237443549.SGD","LU0920783379.SGD","AZN.UK","LU2237443978.SGD","LU2091194634.USD","LU0969580561.USD","LU2237443895.HKD","LU0211327993.USD","LU1119994496.HKD","LU0889566641.SGD","IE0002141913.USD","LU1064927863.SGD","LU1104425308.USD","LU1496350502.SGD","LU0997586515.USD","LU1880407132.USD","LU0345777659.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0310799852.SGD","LU1046234339.USD","LU2539964713.USD","LU0972486137.USD","LU0114720955.EUR","LU0857590862.USD","LU1267930573.SGD","LU2357627491.SGD","LU0266013472.USD","LU2125909593.SGD","LU0128525929.USD","LU2293690082.USD","LU0949170426.SGD","LU0171293334.USD","IE00BJT1NW94.SGD","LU1019634622.SGD","LU1153584641.USD","LU1003077747.HKD","LU0203345920.USD","LU1481600234.SGD","LU0738911758.USD","LU0827474353.SGD","SG9999013999.USD","LU2237443382.USD","BK0239","LU0557290698.USD","LU2237443622.USD","LU1170363599.USD","LU1061106388.HKD","LU1355424745.HKD","LU0784384876.USD","SGXZ57979304.SGD","LU0823399737.USD","LU1989772923.USD","LU1923622614.USD","LU1019632923.USD","LU1814569148.SGD","BK5011","LU0029864427.USD","LU2108987350.USD","LU1267930813.SGD","LU0757432116.USD","LU0575583348.USD","LU0289739699.SGD","03165","LU2089984988.USD","LU0949170772.SGD","LU1267930227.SGD","LU2133065610.SGD","LU0390134368.USD","LU0661504455.SGD","LU1261432733.SGD","LU0077335932.USD","LU0553294199.USD","LU1051770623.HKD","LU0920840948.USD","LU1078025761.USD","LU0823416689.USD","LU0882574055.USD","LU0203347892.USD","LU0011850046.USD","IE00B3T34201.USD","LU0310800379.SGD","LU0058720904.USD","LU2433249047.HKD","LU0499090636.EUR","LU1084165304.USD","LU0171276677.USD","LU1496350171.SGD","LU2112291526.USD","LU0792757196.USD","LU1301847155.USD","LU1015430645.USD","LU2279689827.SGD","LU0047473722.EUR","LU0859254822.USD","LU0964806797.USD","SG9999001176.USD","688192","LU0345777147.USD","LU0211326839.USD","LU0960981461.USD","LU0957799991.USD","IE00BFTCPJ56.SGD","LU0496365809.HKD","LU1481599808.USD","LU0310800965.SGD","LU1323610961.USD","LU1989772840.SGD","LU1989771016.USD","LU1273509221.SGD","LU0640478417.SGD","LU0432979614.USD","IE00BKPKM643.USD","LU1057294990.SGD","LU1196032939.SGD","LU0047473722.SGD","LU1880407215.USD","LU2355687059.USD","LU1983299246.USD","LU0128525689.USD","LU0976567544.SGD","IE0009355771.USD","LU0158827948.USD","LU1291159041.SGD","LU2089283258.USD","LU2293690249.USD","LU2324357040.USD","LU2023251221.USD","LU0784385840.USD","LU2237443465.HKD","LU2468319806.SGD","IE00B2B36J28.USD","LU0889565080.SGD","LU0784385170.HKD","LU1829250122.USD","LU0526926950.USD","LU0887340254.USD","LU2089284900.SGD","LU0997586432.USD","LU0963555726.SGD","LU0211328371.USD","LU0211326755.USD","SG9999001176.SGD","LU1487256676.USD","LU1153585028.USD","LU1003076772.USD","LU1023059063.AUD","IE0034235188.USD","LU0122379950.USD","LU0545039389.USD","LU0052756011.USD","LU0708994859.HKD","LU2114397693.USD","LU1267930490.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651168121","title":"异动快报：迪哲医药-U（688192）7月14日13点0分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2651168121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651168121?lang=zh_cn&edition=full","pubTime":"2026-07-14 13:05","pubTimestamp":1784005553,"startTime":"0","endTime":"0","summary":"证券之星7月14日盘中消息，13点0分迪哲医药-U（688192）触及涨停板。其所属行业化学制药目前上涨。领涨股为ST南新。该股为医药，创新药概念热股，当日医药概念上涨1.18%，创新药概念上涨0.62%。7月13日的资金流向数据方面，主力资金净流入2756.39万元，占总成交额6.99%，游资资金净流出1696.3万元，占总成交额4.3%，散户资金净流出1060.08万元，占总成交额2.69%。近5日资金流向一览见下表：迪哲医药-U主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400021347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK1515","BK1574","BK1161","09939","159938","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649694872","title":"每周股票复盘：迪哲医药（688192）因股价涨幅偏离值累计达30%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2649694872","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649694872?lang=zh_cn&edition=full","pubTime":"2026-07-05 01:44","pubTimestamp":1783187055,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，迪哲医药报收于48.48元，较上周的36.49元上涨32.86%。本周，迪哲医药7月3日盘中最高价报49.0元。本周关注点来自交易信息汇总：迪哲医药因连续3个交易日收盘价涨幅偏离值累计达30%登上龙虎榜。公司公告汇总迪哲（江苏）医药股份有限公司股票交易异常波动公告迪哲（江苏）医药股份有限公司股票于2026年7月1日至7月3日连续三个交易日内收盘价格涨幅偏离值累计达到30%，构成股票交易异常波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","09939","BK0239","BK1574","159938","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788301682863,"stockEarnings":[{"period":"1week","weight":-0.039},{"period":"1month","weight":0.1332},{"period":"3month","weight":0.3741},{"period":"6month","weight":0.1916},{"period":"1year","weight":-0.2848},{"period":"ytd","weight":0.0043}],"compareEarnings":[{"period":"1week","weight":0.0233},{"period":"1month","weight":0.0385},{"period":"3month","weight":-0.0255},{"period":"6month","weight":-0.0313},{"period":"1year","weight":0.0269},{"period":"ytd","weight":0.0028}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12936人(较上一季度增加18.73%)","perCapita":"35653股","listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","registeredCapital":"46516万元","survey":" 迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。","listedPrice":52.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药-U(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药-U(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药-U,688192,迪哲医药-U股票,迪哲医药-U股票老虎,迪哲医药-U股票老虎国际,迪哲医药-U行情,迪哲医药-U股票行情,迪哲医药-U股价,迪哲医药-U股市,迪哲医药-U股票价格,迪哲医药-U股票交易,迪哲医药-U股票购买,迪哲医药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药-U(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药-U(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}